Skip to main content
SpringerLink
Log in

Is Reporting of Recurrence Data Important in Pancreatic Cancer?

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Therapeutic approaches to patients with pancreatic cancer have undergone a paradigm shift in recent years. However, little is known about the outcome of patients with recurrent pancreatic cancer who undergo treatment. The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome.

Methods: A review of all patients undergoing surgical resection with curative intent revealed 70 patients with documented recurrence and complete medical records. Patients were grouped into three categories: group 1 included those who received treatment after recurrence (n = 45), group 2 included those who were not offered treatment (n = 9), and group 3 included those with poor performance status who received no treatment (n = 16).

Results: The median overall survival for the three groups was 26, 18, and 14.5 months for groups 1, 2, and 3, respectively (P < .00001). The median survival after recurrence was 10 months, 6 months, and 1 month, respectively, for the three groups (P < .0001).

Conclusions: This is the first series we are aware of that compares the outcomes of patients who received treatment after recurrence of pancreatic cancer with the outcomes of those who received no treatment. In this series, it seems that patients who were well enough to tolerate additional therapy had a longer survival than those who received supportive care only. This may be important in the analysis of adjuvant therapy trials of pancreatic cancer with survival as an end point.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.

    PubMed  Google Scholar 

  2. Karpoff HM, Klimstra DS, Brennan MF, Conlon KC. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg 2001;136:44–7; discussion 48.

    PubMed  CAS  Google Scholar 

  3. Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997;84:1370–6.

    Article  CAS  PubMed  Google Scholar 

  4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–79.

    Article  CAS  PubMed  Google Scholar 

  5. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195–210434_2004_Article_304.

    Article  CAS  PubMed  Google Scholar 

  6. van Heerden JA, McIlrath DC, Ilstrup DM, Weiland LH. Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update. World J Surg 1988;12:658–62.

    PubMed  CAS  Google Scholar 

  7. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56–61.

    CAS  PubMed  Google Scholar 

  8. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–10.

    CAS  PubMed  Google Scholar 

  9. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.

    CAS  PubMed  Google Scholar 

  10. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13.

    CAS  PubMed  Google Scholar 

  11. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347–53.

    PubMed  CAS  Google Scholar 

  12. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202–8.

    PubMed  CAS  Google Scholar 

  13. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.

    Google Scholar 

  14. Tajiri H, Yoshimori M, Okazaki N, Miyaji M. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 1991;48:18–21.

    Article  PubMed  CAS  Google Scholar 

  15. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995;13:748–55.

    PubMed  CAS  Google Scholar 

  16. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576–85.

    Article  CAS  PubMed  Google Scholar 

  17. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758–68.

    Article  CAS  PubMed  Google Scholar 

  18. Pinpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121–30.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Michael O. Meyers MD, Ingrid M. Meszoely MD, John P. Hoffman MD, James C. Watson MD & Burton L. Eisenberg MD

  2. Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Eric Ross PhD

  3. Department of Surgery, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA, 19111

    John P. Hoffman MD

Authors
  1. Michael O. Meyers MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid M. Meszoely MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John P. Hoffman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James C. Watson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Ross PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Burton L. Eisenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Hoffman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyers, M.O., Meszoely, I.M., Hoffman, J.P. et al. Is Reporting of Recurrence Data Important in Pancreatic Cancer?. Ann Surg Oncol 11, 304–309 (2004). https://doi.org/10.1245/ASO.2004.03.040

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.03.040

Key Words

Search

Navigation